List view / Grid view
Oral small molecule treatment Brinsupri (brensocatib) could become a new…
Oral small molecule treatment Brinsupri (brensocatib) could become a new standard of care for patients with the progressive lung disease.
The small molecule treatment is currently being reviewed by the…
The small molecule treatment is currently being reviewed by the US Food and Drug Administration (FDA), under the Prescription Drug User Fee Act (PDUFA).
The drug candidate SFX-01 is set to be studied in…
The drug candidate SFX-01 is set to be studied in Phase II/III trials to test its efficacy at treating acute respiratory distress syndrome (ARDS), a complication of COVID‐19.
